CN1267407C - 兴奋性氨基酸前体药物 - Google Patents

兴奋性氨基酸前体药物 Download PDF

Info

Publication number
CN1267407C
CN1267407C CNB018219667A CN01821966A CN1267407C CN 1267407 C CN1267407 C CN 1267407C CN B018219667 A CNB018219667 A CN B018219667A CN 01821966 A CN01821966 A CN 01821966A CN 1267407 C CN1267407 C CN 1267407C
Authority
CN
China
Prior art keywords
compound
amino
formula
pharmaceutically acceptable
hexane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB018219667A
Other languages
English (en)
Chinese (zh)
Other versions
CN1486298A (zh
Inventor
D·S·科菲
J·A·蒙
S·W·彼得森
C·佩德雷加尔－特尔切罗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP01500263A external-priority patent/EP1310480A1/en
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CN1486298A publication Critical patent/CN1486298A/zh
Application granted granted Critical
Publication of CN1267407C publication Critical patent/CN1267407C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/12—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/46—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C229/50—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups and carboxyl groups bound to carbon atoms being part of the same condensed ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/18—All rings being cycloaliphatic the ring system containing six carbon atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Anesthesiology (AREA)
CNB018219667A 2001-01-11 2001-12-14 兴奋性氨基酸前体药物 Expired - Fee Related CN1267407C (zh)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
EP01500007.8 2001-01-11
EP01500007 2001-01-11
EP01500206.6 2001-08-02
EP01500206 2001-08-02
US32978601P 2001-10-16 2001-10-16
US60/329786 2001-10-16
EP01500263.7 2001-11-07
EP01500263A EP1310480A1 (en) 2001-11-07 2001-11-07 Prodrugs of excitatory amino acids

Publications (2)

Publication Number Publication Date
CN1486298A CN1486298A (zh) 2004-03-31
CN1267407C true CN1267407C (zh) 2006-08-02

Family

ID=27440162

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB018219667A Expired - Fee Related CN1267407C (zh) 2001-01-11 2001-12-14 兴奋性氨基酸前体药物

Country Status (24)

Country Link
US (1) US7256217B2 (enExample)
EP (1) EP1368304B1 (enExample)
JP (1) JP4064237B2 (enExample)
KR (1) KR20030090622A (enExample)
CN (1) CN1267407C (enExample)
AR (1) AR036007A1 (enExample)
AT (1) ATE356111T1 (enExample)
AU (1) AU2002228737B2 (enExample)
BR (1) BR0116770A (enExample)
CA (1) CA2433667C (enExample)
CZ (1) CZ303490B6 (enExample)
DE (1) DE60127182T2 (enExample)
DZ (1) DZ3461A1 (enExample)
ES (1) ES2282315T3 (enExample)
HU (1) HUP0400620A3 (enExample)
IL (1) IL156364A0 (enExample)
MX (1) MXPA03006186A (enExample)
NO (1) NO20033166L (enExample)
NZ (1) NZ526050A (enExample)
PE (1) PE20020829A1 (enExample)
PL (1) PL208413B1 (enExample)
SK (1) SK287934B6 (enExample)
SV (1) SV2003000836A (enExample)
WO (1) WO2002055481A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20090058A2 (hr) 2002-06-11 2009-04-30 Eli Lilly And Company Prekursorski oblici lijekova za aminokiseline s pobuđivačkom aktivnosti
WO2010111080A2 (en) 2009-03-27 2010-09-30 Eli Lilly And Company Optimized treatment of schizophrenia
AR079343A1 (es) * 2009-12-21 2012-01-18 Lilly Co Eli Compuesto de acido 2-amino-4-(4h-1,2,4-triazol-3-ilsulfanil)biciclo[3.1.0]hexano-2,6-dicarboxilico, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar un trastorno psiquiatrico
HRP20160676T1 (hr) 2011-06-17 2016-07-15 Eli Lilly And Company Derivati biciklo[3.1.0]heksan-2,6-dikarboksilne kiseline kao agonisti receptora mglu2
AR089718A1 (es) 2012-02-01 2014-09-10 Lilly Co Eli AGONISTAS DE mGlu2/3
TWI809089B (zh) 2018-04-17 2023-07-21 德商拜耳廠股份有限公司 用於製備具有酸不穩定的酮保護基團官能之n-醯化胺基酸酯的方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL182285B1 (pl) 1994-08-12 2001-12-31 Lilly Co Eli Syntetyczne aminokwasy oraz ich estry i srodki farmaceutyczne je zawierajace PL PL PL PL PL PL PL
CA2195782A1 (en) 1994-08-12 1996-02-22 David Reed Helton Composition and method for treating anxiety
US5750566A (en) * 1994-08-12 1998-05-12 Eli Lilly And Company Synthetic excitatory amino acids
IL118727A (en) 1995-06-29 2003-01-12 Lilly Co Eli (-)-2-spiro-5-hydantoinbicyclo [3.1.0] hexane-6-carboxylic acid, salts thereof and use thereof for the preparation of (+)-(2) aminobicyclo [3.1.0] hexane-2,6-dicarboxylic acid
ZA983930B (en) * 1997-05-14 1999-11-08 Lilly Co Eli Excitatory amino acid receptor modulators.
DK1052246T3 (da) 1998-01-28 2003-06-16 Taisho Pharmaceutical Co Ltd Fluorholdige aminosyrederivater
GB9815542D0 (en) 1998-07-17 1998-09-16 Lilly Co Eli Bicyclohexane derivatives
US6528499B1 (en) 2000-04-27 2003-03-04 Georgetown University Ligands for metabotropic glutamate receptors and inhibitors of NAALADase
EP1351925A1 (en) 2001-01-11 2003-10-15 Eli Lilly And Company Prodrugs of excitatory amino acids
WO2003006489A2 (en) 2001-07-09 2003-01-23 Eli Lilly And Company Prodrugs of excitatory amino acids
EP1463713A1 (en) 2001-11-23 2004-10-06 Eli Lilly And Company Prodrugs of excitatory amino acids
WO2003057661A1 (en) 2001-12-21 2003-07-17 Eli Lilly And Company Prodrugs of excitatory amino acids

Also Published As

Publication number Publication date
JP2004524292A (ja) 2004-08-12
MXPA03006186A (es) 2004-02-13
EP1368304B1 (en) 2007-03-07
PE20020829A1 (es) 2002-09-21
WO2002055481A8 (en) 2003-10-02
SK8262003A3 (en) 2004-01-08
AU2002228737B2 (en) 2007-01-04
US20040121962A1 (en) 2004-06-24
ATE356111T1 (de) 2007-03-15
NO20033166D0 (no) 2003-07-10
US7256217B2 (en) 2007-08-14
JP4064237B2 (ja) 2008-03-19
HUP0400620A2 (hu) 2004-12-28
BR0116770A (pt) 2003-12-23
NO20033166L (no) 2003-09-09
EP1368304A1 (en) 2003-12-10
SV2003000836A (es) 2003-01-13
CA2433667C (en) 2011-06-14
CN1486298A (zh) 2004-03-31
CZ20031916A3 (en) 2004-03-17
IL156364A0 (en) 2004-01-04
HUP0400620A3 (en) 2012-09-28
NZ526050A (en) 2005-03-24
DZ3461A1 (fr) 2002-07-18
DE60127182T2 (de) 2007-11-22
KR20030090622A (ko) 2003-11-28
PL208413B1 (pl) 2011-04-29
SK287934B6 (sk) 2012-05-03
WO2002055481A1 (en) 2002-07-18
CZ303490B6 (cs) 2012-10-17
AR036007A1 (es) 2004-08-04
DE60127182D1 (de) 2007-04-19
CA2433667A1 (en) 2002-07-18
PL361669A1 (en) 2004-10-04
ES2282315T3 (es) 2007-10-16

Similar Documents

Publication Publication Date Title
JP7012117B2 (ja) リルゾールプロドラッグおよびそれらの使用
TWI846527B (zh) 一種多功能化合物、其製備方法及其在醫藥上的應用
CN1041827C (zh) 被取代的3－氨基奎宁环化合物的制备方法
JP5815746B2 (ja) Ｃ型肝炎ウイルス阻害剤
TW202237616A (zh) 螺旋吡咯烷衍生的化合物、醫藥組合物及其用途
CN101031572A (zh) (r/s)利福霉素衍生物，它们的制备和药物组合物
CN1279673A (zh) (环)烷基取代的)－γ－氨基丁酸衍生物(=GABA类似物),其制备和在治疗神经病中的用途
CA3113463A1 (en) Nitroxoline prodrug and use thereof
CN1192144A (zh) 1h－4(5)－取代的咪唑衍生物
CN1039910C (zh) 雪花胺衍生物、其制备方法及其作为药物的用途
CN1267407C (zh) 兴奋性氨基酸前体药物
CN1340044A (zh) 莫维诺林衍生物
JP2024511881A (ja) ＳＡＲＳ－ＣＯＶ－２ Ｍｐｒｏ阻害剤化合物
CN1255926A (zh) 20(s)一喜树碱的糖结合物
CN1199987C (zh) 具有nk2拮抗剂作用的碱性单环化合物,其制备方法,和含有它们的制剂
CN1902213A (zh) 异黄酮类前药、其组合物和涉及它们的治疗方法
CN1212835C (zh) 含异羟肟酸酯的半胱氨酸和丝氨酸蛋白酶抑制剂
CN1468219A (zh) 哌啶衍生物及含这些衍生物作为有效成分的药物
JPH07500604A (ja) 高血圧治療用エチルアラニンアミノジオール化合物
CN1511043A (zh) 坡加巴伯灵乳糖缀合物
CN1373770A (zh) 假单胞菌素前药
CN1198748A (zh) 多氟烷基色氨酸三肽凝血酶抑制剂
CN1056420A (zh) 制备含2-甲氧基甲基-青霉烯衍生物的药用组合物方法
CN1255131A (zh) 作为氧化氮合酶抑制剂的脒衍生物
CN1100054C (zh) 由(2s)－4－吡啶甲基－2－哌嗪－叔丁基甲酰胺制备hiv蛋白酶抑制剂的方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1064361

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1064361

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20060802

Termination date: 20151214

EXPY Termination of patent right or utility model